Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced
Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of
Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease ("GD") and thyroid eye disease ("TED")
Dosing
